Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/21396
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Grossmann, Mathis | - |
dc.contributor.author | Ramchand, Sabashini K | - |
dc.contributor.author | Milat, Frances | - |
dc.contributor.author | Vincent, Amanda | - |
dc.contributor.author | Lim, Elgene | - |
dc.contributor.author | Kotowicz, Mark A | - |
dc.contributor.author | Hicks, Jill | - |
dc.contributor.author | Teede, Helena J | - |
dc.date | 2019-07-18 | - |
dc.date.accessioned | 2019-08-12T05:00:08Z | - |
dc.date.available | 2019-08-12T05:00:08Z | - |
dc.date.issued | 2019-09 | - |
dc.identifier.citation | Medical Journal of Australia 2019; 211(5): 224-229 | en_US |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/21396 | - |
dc.description.abstract | Representatives appointed by relevant Australian medical societies used a systematic approach for adaptation of guidelines (ADAPTE) to formulate clinical consensus recommendations on assessment and management of bone health in women with oestrogen receptor-positive early breast cancer receiving endocrine therapy. The current evidence suggests that women receiving adjuvant aromatase inhibitors and pre-menopausal woman treated with tamoxifen have accelerated bone loss and that women receiving adjuvant aromatase inhibitors have increased fracture risk. Both bisphosphonates and denosumab prevent bone loss; additionally, denosumab has proven anti-fracture benefit in post-menopausal women receiving aromatase inhibitors for hormone receptor-positive breast cancer. Women considering endocrine therapy need fracture risk assessment, including clinical risk factors, biochemistry and bone mineral density measurement, with monitoring based on risk factors. Weight-bearing exercise and vitamin D and calcium sufficiency are recommended routinely. Anti-resorptive treatment is indicated in women with prevalent or incident clinical or morphometric fragility fractures, and should be considered in women with a T score (or Z score in women aged < 50 years) of < - 2.0 at any site, or if annual bone loss is ≥ 5%, considering baseline bone mineral density and other fracture risk factors. Duration of anti-resorptive treatment can be individualised based on absolute fracture risk. Relative to their skeletal benefits, risks of adverse events with anti-resorptive treatments are low. Skeletal health should be considered in the decision-making process regarding choice and duration of endocrine therapy. Before and during endocrine therapy, skeletal health should be assessed regularly, optimised by non-pharmacological intervention and, where indicated, anti-resorptive treatment, in an individualised, multidisciplinary approach. | en_US |
dc.language.iso | eng | - |
dc.subject | Breast neoplasms | en_US |
dc.subject | Osteoporosis | en_US |
dc.title | Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary. | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Medical Journal of Australia | en_US |
dc.identifier.affiliation | University of Melbourne, Melbourne, VIC | en_US |
dc.identifier.affiliation | Austin Health | en_US |
dc.identifier.affiliation | Barwon Health, Geelong | en_US |
dc.identifier.affiliation | Deakin University, Geelong, VIC | en_US |
dc.identifier.affiliation | Monash Medical Centre, Melbourne, VIC | en_US |
dc.identifier.affiliation | Monash University, Melbourne, VIC | en_US |
dc.identifier.affiliation | Monash Centre for Health Research and Implementation, Monash University, Melbourne, VIC | en_US |
dc.identifier.affiliation | Garvan Institute of Medical Research, Sydney, NSW | en_US |
dc.identifier.affiliation | Consumer Representative, Breast Cancer Network Australia, Melbourne, VIC | en_US |
dc.identifier.affiliation | Monash Partners Academic Health Sciences Centre, Monash University, Melbourne, VIC | en_US |
dc.identifier.doi | 10.5694/mja2.50280 | en_US |
dc.type.content | Text | en_US |
dc.identifier.orcid | 0000-0001-8261-3457 | en_US |
dc.identifier.orcid | 0000-0001-7609-577X | en_US |
dc.identifier.orcid | 0000-0001-8261-3457 | en_US |
dc.identifier.pubmedid | 31318068 | - |
dc.type.austin | Journal Article | - |
local.name.researcher | Grossmann, Mathis | |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Endocrinology | - |
crisitem.author.dept | Endocrinology | - |
crisitem.author.dept | Medicine (University of Melbourne) | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.